Mutated ASXL1 upregulates mTOR expression in renal cell carcinoma with fibromyomatous stroma-Reference-Cited by-同舟云学术

Mutated ASXL1 upregulates mTOR expression in renal cell carcinoma with fibromyomatous stroma

Published:2023-12-16 Issue: Volume: Page:
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Liu Yang,Zhou Luting,Xu Haimin,Gu Yijin,Dong Lei,Yang Xiaoqun,Wang Chaofu^ORCID

Funder

National Natural Science Foundation of China

Science and Technology Commission of Shanghai Municipality

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00428-023-03667-7.pdf

Reference15 articles.

1. International Agency for Research on Cancer (IARC) and H. Moch (2016) WHO classification of tumours of the urinary system and male genital organs. 4th edition. ed. World Health Organization classification of tumours. Lyon: International Agency for Research on Cancer. 356 pages

2. Trpkov K et al (2021) Novel, emerging and provisional renal entities: the Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol 34(6):1167–1184

3. Gournay M et al (2021) Renal cell carcinoma with leiomyomatous stroma in tuberous sclerosis complex: a distinct entity. Virchows Arch 478(4):793–799

4. Tjota MY et al (2023) TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases. Hum Pathol 134:124–133

5. Shah RB et al (2020) “Renal cell carcinoma with leiomyomatous stroma” harbor somatic mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): clinicopathologic and molecular characterization of 18 sporadic tumors supports a distinct entity. Am J Surg Pathol 44(5):571–581